MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system

Gustavo Tapia, Maria Joao Baptista, Ana Maria Muñoz-Marmol, Ayman Gaafar, Maria Puente-Pomposo, Olga Garcia, Ruth Marginet-Flinch, Carolina Sanz, Jose Tomas Navarro, Juan Manuel Sancho, Josep Maria Ribera, Aurelio Ariza, Jose Luis Mate

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)

Abstract

© 2015 APMIS. Published by John Wiley & Sons Ltd. MYC and BCL2 gene translocations and protein expression have recently demonstrated to be of prognostic significance in systemic diffuse large B-cell lymphoma (DLBCL). However, their role in primary central nervous system DLBCL (CNS-DLBCL) prognosis has been scarcely analyzed. We studied the immunophenotype, the status of the MYC, BCL2, and BCL6 genes and the clinical features of a series of 42 CNS-DLBCL and evaluated their prognostic significance. We found high MYC protein expression in 43% of cases, and this was associated with lower overall survival (OS). Cases with concurrent expression of MYC and BCL2 showed a lower OS, although the difference did not reach statistical significance. Translocations involving the MYC or BCL2 genes were not detected. The BCL6 gene was frequently translocated, but was unrelated to survival. We conclude that MYC protein expression detected by immunohistochemistry identifies a CNS-DLBCL subset with worse prognosis and may contribute to a more accurate risk stratification of CNS-DLBCL patients.
Original languageEnglish
Pages (from-to)596-603
JournalAPMIS
Volume123
Issue number7
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • BCL2
  • Immunohistochemistry
  • MYC
  • Primary CNS lymphoma
  • Prognosis

Fingerprint

Dive into the research topics of 'MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system'. Together they form a unique fingerprint.

Cite this